53,402 Shares in Dynavax Technologies Corporation $DVAX Bought by GSA Capital Partners LLP

GSA Capital Partners LLP acquired a new position in Dynavax Technologies Corporation (NASDAQ:DVAX) during the third quarter, according to the company in its most recent filing with the SEC. The fund acquired 53,402 shares of the biopharmaceutical company’s stock, valued at approximately $530,000.

Several other large investors also recently modified their holdings of the business. Hantz Financial Services Inc. lifted its stake in shares of Dynavax Technologies by 236.9% in the third quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 2,710 shares in the last quarter. LSV Asset Management purchased a new stake in Dynavax Technologies during the 3rd quarter worth approximately $89,000. Osaic Holdings Inc. increased its holdings in Dynavax Technologies by 15.1% during the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 1,226 shares during the last quarter. Summit Global Investments acquired a new position in shares of Dynavax Technologies in the 3rd quarter valued at approximately $113,000. Finally, Catalyst Funds Management Pty Ltd purchased a new position in shares of Dynavax Technologies during the 2nd quarter valued at approximately $121,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. William Blair lowered shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research note on Wednesday, December 24th. Wall Street Zen raised shares of Dynavax Technologies to a “strong-buy” rating in a report on Saturday, February 14th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus price target of $21.00.

Dynavax Technologies Stock Performance

Dynavax Technologies stock opened at $15.50 on Tuesday. Dynavax Technologies Corporation has a 1 year low of $9.20 and a 1 year high of $15.73. The firm’s 50-day moving average is $14.95 and its 200-day moving average is $12.00. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.94 and a current ratio of 7.62. The company has a market cap of $1.82 billion, a P/E ratio of -41.89 and a beta of 0.97.

Insider Activity at Dynavax Technologies

In other news, COO David F. Novack sold 114,000 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $15.64, for a total transaction of $1,782,960.00. Following the completion of the transaction, the chief operating officer directly owned 63,344 shares of the company’s stock, valued at approximately $990,700.16. This represents a 64.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.98% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.